Human Organ Chips Reveal New Inflammatory Bowel Disease Drivers

Alican Özkan[1], Gwenn E. Merry[1], David B. Chou[1,2], Ryan R. Posey[1], Anna Stejskalova[1], Karina Calderon[1], Megan Sperry[1], Joshua Piatok[1], Viktor Horvath[1,10], Lorenzo E. Ferri[3,4], Emanuela Carlotti[5], Stuart A. C. McDonald[5], Douglas J. Winton[6], Rocco Riccardi[7], Liliana Bordeianou[7], Sean Hall[1,11], Girija Goyal[1], Donald E. Ingber[1,8,9,*]

[1] Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA
[2] Department of Pathology, Massachusetts General Hospital, Boston, MA
[3] Thoracic and Upper GI Cancer Research Laboratories, Research Institute of McGill University Health Centre, Montreal, QC, Canada
[4] Department of Experimental Surgery and Department of Surgery, McGill University, Montreal, QC, Canada
[5] Clonal Dynamics in Epithelia Laboratory, Queen Mary University of London, London, United Kingdom
[6] Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, United Kingdom
[7] Department of Surgery, Massachusetts General Hospital, Boston, MA
[8] Vascular Biology Program and Department of Surgery, Boston Children's Hospital and Harvard Medical School, Boston, MA
[9] Harvard John A. Paulson School of Engineering and Applied Sciences, Cambridge, MA
[10] Current address: Entact Bio, Watertown, MA
[11] Current address: Iovance Therapeutics, Tampa, FL

*Address correspondence to: Donald E. Ingber, MD, PhD
201 Brookline Ave., Suite 401, Boston MA, 02215, USA
em: don.ingber@wyss.harvard.edu

Keywords: Organ-on-a-chip, Ulcerative Colitis, Crohn's Disease, Carcinogenesis, Epithelial-Stromal Interactions

Abstract

Inflammatory bowel disease (IBD) patients exhibit compromised intestinal barrier

function and decreased mucus accumulation, as well as increased inflammation,

fibrosis, and cancer risk, with symptoms often being exacerbated in women during

pregnancy. Here, we show that these IBD hallmarks can be replicated using human

Organ Chips lined by IBD patient-derived colon epithelial cells interfaced with matched

fibroblasts cultured under flow. Use of heterotypic tissue recombinants revealed that IBD

fibroblasts are the primary drivers of multiple IBD symptoms. Inflammation and fibrosis

are accentuated by peristalsis-like motions in IBD Chips and when exposed to

pregnancy-associated hormones in female IBD Chips. Carcinogen exposure also

increases inflammation, gene mutations, and chromosome duplication in IBD Chips, but

not in Healthy Chips. These data enabled by human Organ Chip technology suggest that

the intestinal stroma, sex hormones, and peristalsis-associated mechanical deformations

play a key role in driving inflammation, fibrosis, and disease progression in male and

female IBD patients.

____

Main

Inflammation of the intestinal mucosa, including enhanced production of inflammatory cytokines

and tissue infiltration with immune cells, along with increased barrier permeability, thinning of

the protective mucus layer, and fibrosis are central hallmarks of inflammatory bowel diseases

(IBD), such as Crohn's disease (CD) and ulcerative colitis (UC). These alterations lead to

significant digestive issues and an increased risk of developing colorectal cancer[1]. IBD

symptoms also can be more prominent in women[2] and they have to control their symptoms

before pregnancy because many of these patients experience exacerbations that increase the

risk of preterm birth[3]. Most IBD treatments target immune cells rather than intestinal tissues, and

treatment efficacy is variable among patients[4]. However, interactions between epithelia and

underlying stroma also may contribute to inflammation as well as cancer progression[5]. For

example, the presence of a subset of fibroblasts that recruit immune cells to the intestinal stem

cell niche is associated with poor prognosis in patients with colorectal cancer[6]. Inflamed

epithelial cells also can undergo an epithelial-to-mesenchymal transition and increase

deposition of extracellular matrix (ECM) resulting in intestinal fibrosis that leads to

complications, such as bowel stiffening and restriction of lumenal fluid flow, which further

exacerbate digestive problems in IBD patients [7,8]. Thus, there is a need to gain greater insight

into how epithelial-stromal interactions, peristalsis, and fluid flow influence IBD development in

both male and female patients. However, animal IBD models and in vitro studies with human

intestinal cell lines lack direct relevance to the human disease[9], and human intestinal organoids

cannot be used to address these questions because they lack an epithelial-stromal interface,

mucosal barrier, fluid flow, peristalsis motions, and immune cells, which are critical organ-level

features required to address these questions.

Here, we leveraged human organ-on-a-chip (Organ Chip) microfluidic culture technology

that recreates tissue-tissue interfaces and a physiologically relevant intestinal microenvironment

including dynamic fluid flow, peristalsis-like mechanical deformations, and circulating immune

cells to confront this challenge[10,11]. Colon Chips lined by human organoid-derived colonic

epithelium cultured under dynamic fluid flow have been successfully used in the past to study

mucus layer accumulation and physiology[12,13] as well as to identify microbiome metabolites that

influence host response to bacterial infections[14]. In this study, we isolated epithelium and

stromal-derived fibroblasts from the same regions of colon from healthy or IBD patients and

used them to create Colon Chips that contained an epithelial-fibroblast interface. We also

created heterotypic tissue recombinant chips, measured the effects of applying peristalsis-like

motions and flowing immune cells through the stromal channel, and studied the effects of

female hormones on the IBD state, in addition to modeling cancer progression by exposing the

Colon Chips to carcinogens in vitro.

Results

Establishment of Human Healthy and IBD Colon Chips

Patient-specific epithelial organoids and stromal fibroblasts were isolated from surgical

resections of the colon of healthy and IBD patients with CD or UC (**Extended Data Fig. 1A** and

Supplementary Information) and the organoids were expanded in Matrigel cultures while the

fibroblasts were cultured on plastic dishes (**Extended Data Fig. 1B**). To build the human Colon

Chips, the primary colon epithelial cells and fibroblasts were respectively seeded on the top and

bottom surfaces of a porous ECM-coated membrane that separates two parallel channels within

a commercially available microfluidic Organ Chip (**Fig. 1A**). The cells were allowed to adhere

under static conditions for 1 day before flow was initiated. A continuous epithelial monolayer

with undulating crypt-like structures formed by 11 days in Healthy Chips when viewed from

above (**Fig. 1B,C**) or in cross sections (**Fig. 1D,E**). The epithelium became progressively

obscured by dense opaque deposits from day 3 to 7, which completely filled the upper channel

by day 11 (**Fig. 1C**). These opaque materials have been shown to be composed of mucus with

similar composition, thickness, and bilayer structure as seen in human colonic mucus in vivo

[12,13]. Similar chips lined with colonic epithelium and fibroblasts from CD or UC patient samples

also formed hill and crypt-like structures, but significantly less mucus accumulated on top of the

epithelium, particularly in the UC chips (**Fig. 1C** and **Extended Data Fig. 1C**). Analysis of

vertical cross-sectional views of the intestinal epithelium cultured in chips revealed that the

heights of the undulating epithelial layerwere significantly reduced in the IBD chips as well (**Fig.**

1D and Extended Data Fig. 1D). Epithelial cells within both Healthy and IBD Chips also

expressed colon-specific cytokeratin 20 along their apical borders, while the basal stem cell

marker SOX9 primarily appeared in their nuclei at the cell base (**Fig. 1F**), which is a hallmark of

colon crypts in vivo [15].

Past work has shown that there is a subset of stromal fibroblasts in IBD patients that

have higher levels of expression of oncostatin M receptor (OSMR) and podoplanin (PDPN)[6],

which appear to play a significant role in inflammation, fibrosis, and cancer[16]. Indeed, when we

carried out flow cytometric analysis after removing stromal cells from the chips, we found that

PDPN expression was significantly higher in IBD fibroblasts that expressed high OSMR levels

(**Extended Data Fig. 2A,B**) and that fibroblasts in IBD Chips lined by cells from both CD and

UC patients secreted more inflammatory cytokines (e.g, IL6, IL8, MCP-1) from the basal

channel than those in Healthy Chips (**Fig. 1G**). We also found that fibroblasts in IBD Chips

established using both CD and UC patients samples express higher vimentin and α-SMA than

healthy controls (**Extended Data Fig. 2C,D**), as previously observed in IBD mice models

induced by treatment with DSS or IL10 knock out[17].

Transcriptomic analysis of epithelial cells and fibroblasts individually within Healthy

versus IBD Chips revealed that genes which were found to be overexpressed in CD and UC

(e.g., ADA2, APOBEC3B, GSPT2, CD40, ACAN, HLA-DQB1) epithelium on-chip were also

expressed at higher levels in the intestinal epithelium of IBD patients[18–22] compared to healthy

patients (**Extended Data Fig. 3A,B**). In addition, genes suppressed in IBD patient tissues in

vivo (e.g., MUC5B, FDFT1 in CD and SOD3, SMIM32, APOBR in UC [18–22]) were expressed at

lower levels by epithelium in both CD and UC IBD Chips.

When stromal cells cultured in IBD Chips were similarly analyzed, they displayed

expression of IBD-relevant genes with CD fibroblasts overexpressing ITGA7, FXD1, HGF,

FZD7, NKX2-3, LOXL3 relative to healthy fibroblasts, while high levels of IKBIP, NKX2-3, ADA2,

ECM2, NDN, SLC22A17 were seen in UC fibroblasts (**Extended Data. Fig. 3C,D**). In contrast,

other genes were downregulated in these fibroblasts including NLRP2, FUCA1, CLCA4, and

RNF186 in CD and RALGPS1, DLG3, STON2, and FMO5 in UC derived IBD Chips (**Extended**

Data Fig. 3C,D), which is again consistent with results of transcriptomic analyses carried out on

IBD patient tissues[23–25].

Gene ontology and Reactome analysis revealed that multiple IBD-relevant biological

processes, including increased ECM production and remodeling, cell adhesion, and

angiogenesis as well as decreased metabolism were predominant in both CD and UC

epithelium and fibroblasts on-chip, with UC tissues also exhibiting suppressed IL10 signaling

(**Extended Data Fig. 4A-D**). These functional pathways are also activated or suppressed in a

similar manner in IBD patients[26].

Peristalsis-Like Mechanical Motions Enhance IBD Progression

IBD patients experience thinning of the protective mucus layer in their colon[12] and

eventually loss of peristalsis as a consequence of increased fibrosis[7,8], which further exacerbate

their gastrointestinal symptoms. However, it is not known whether cyclic mechanical

deformation of inflamed intestine or fluid flow due to peristalsis could influence IBD disease

progression. To explore this possibility, we cultured Healthy and IBD Chips in the presence or

absence of physiologically relevant cyclic deformations by applying suction to side chambers in

the flexible devices. The healthy and IBD epithelia both accumulated a mucus layer when

exposed to cyclic mechanical deformations were viewed by dark field imaging; however, the

layer was much thinner in the IBD Chips (**Fig. 2A,B**). Transcriptomic analysis confirmed that the

IBD Chips expressed lower levels of most mucins than Healthy Chips under all conditions, and

that while expression of MUC-1,4,12,13,17,3A,5AC, and 5B increased in Healthy Chips

exposed to mechanical strain, only MUC5AC and MUC13 increased in the IBD Chips (**Fig. 2C**).

These data show that peristalsis-like mechanical deformations have a direct effect on mucus

production in the colonic epithelium in both healthy and IBD Chips as fluid flow was constant

under all conditions, and that the IBD epithelium is less effective at maintaining the normal

thickness of the mucus layer in vitro as observed in IBD patients in vivo[12,13].

Interestingly, second harmonic imaging of ECM fiber formation on-chip revealed that

while both CD and UC derived IBD fibroblasts accumulate comparable fibrillar collagen as

healthy cells, these levels increase many fold when the IBD Chips are exposed to peristalsis-

like motions whereas there is no change in Healthy Chips (**Fig. 2D,E**). Atomic force

microscopic analysis carried out in parallel samples from the resections we used to isolate the

patient-derived cells confirmed that this was associated with tissue stiffening (**Extended Data**

Fig. 5A-D). But while transcriptomic analysis showed that there is increased expression of

collagen-associated genes in CD and UC stroma on-chip without mechanical strain, exposure to

peristalsis-like deformations did not result in significant changes in collagen gene expression

(**Fig. 2F**), suggesting that the fibrotic changes we observed resulted from post-transcriptional

alterations. Indeed, pathway analysis confirmed that biological processes associated with

fibrosis per se (ECM organization, collagen formation and fibril organization) were upregulated

in IBD Chips upon exposure to cyclic mechanical deformations (**Extended Fig. 6A**). In addition,

our transcriptomic analysis revealed that expression of different cytochrome P450 subunits was

suppressed in IBD versus Healthy Chips, which is consistent with the observation that the

intestinal tissues of IBD patients experience decreased metabolic activities[27,28]. Importantly,

while peristalsis-like cyclic deformations increased the expression of most of these metabolic

genes in Healthy Chips, this response was not observed in IBD Chips (**Extended Data Fig. 6B**).

Peristalsis-like cyclic deformations also increased barrier permeability in both Healthy

and IBD Chips; however, barrier leakiness always remained higher in IBD Chips (**Extended**

Data Fig. 7A). Mechanical stimulation also enriched expression of inflammation associated

genes in epithelial cells and fibroblasts in both Healthy and IBD Chips (**Fig. 2G**) and this was

supported by transcriptomic analysis, which showed activation of the inflammatory response

pathway in these cells (**Extended Data Fig. 7B**). Importantly, further pathway analysis of this

transcriptomic dataset (**Extended Data Fig. 8**) demonstrated that peristalsis-like deformations

activate pathways associated with IBD progression and exacerbation in the epithelium, including

those involved in cancer, Toll-like receptor signaling, PPAR signaling, and focal adhesion in IBD

epithelium (**Extended Data Fig. 9A**) as well as NOD-like receptor signaling, PDGF signaling,

and cytokine-cytokine receptor interaction in IBD fibroblasts (**Extended Data Fig. 9B**). In

contrast, these pathways that are known to exacerbate colitis in IBD patients[29,30] were not

activated in Healthy Chips under the same mechanical stimulation conditions.

Replicating Sex-Specific Clinical Symptoms of IBD Patients

The gastrointestinal symptoms of female IBD patients become much more prominent

during menstrual periods[2] and their therapies need to be optimized to control their symptoms

before pregnancy due to increased risk of miscarriage, preterm birth and low birthweight[3]. Yet, it

is not known whether these responses are a direct effect of ovarian hormones on the intestine,

which could potentially contribute to the clinical observations observed in patients [31]. To address

this question directly, we exposed healthy and IBD Chips lined by cells from female patients to

estrogen (E2) and medroxyprogesterone acetate (MPA) to recapitulate the menstrual cycle or a

mixture of pregnancy-associated hormones (E2, MPA, human chorionic gonadotropin, prolactin,

and placental lactogen) to mimic the first trimester of pregnancy. Interestingly, exposure to E2

and MPA or the pregnancy-associated hormone mixture, increased the height of crypt-like

epithelial structures both in healthy and IBD chips (**Fig. 3A-C**). We also discovered addition of

E2 and MPA increased fibrosis and exposure to the pregnancy-associated hormone mixture

produced an even greater increase in fibrillar collagen deposition in the stroma of IBD Chips;

however, this was not observed in Healthy Chips (**Fig. 3D, E and Extended Data. Fig. 10).**

Interestingly, exposure to E2, MPA or the pregnancy-associated hormone mixture decreased

overall inflammatory cytokine and chemokine production in Healthy Chips whereas levels of

these inflammatory molecules increased when IBD Chips were exposed to the same hormones

(**Fig. 3F).**

Stromal Fibroblasts Control Barrier Permeability and Epithelial Inflammation

To better understand the role of fibroblasts in IBD, we took advantage of the synthetic

biology nature of human Organ Chip technology to create chips lined by heterotypic tissue

recombinants of healthy epithelium with IBD stroma and vice versa. As expected, the homotypic

cultures of IBD epithelium and stroma had a compromised barrier with higher permeability than

healthy epithelium and stroma recombinants (**Fig. 4A**). However, we discovered that the

presence of the IBD fibroblasts was the key driver of barrier disruption as permeability increased

significantly when they were combined healthy epithelium in tissue recombinant chips, even

though there was no difference in permeability when the different epithelia were cultured alone

(**Fig. 4A)**. Interestingly, the permeability of the IBD epithelium alone (i.e., without IBD stroma)

was similar to that of healthy epithelium with or without healthy fibroblasts, and tissue

recombinants combining healthy fibroblasts with IBD epithelium also did not further alter barrier

function, again emphasizing the key role of that the IBD stroma plays in terms of compromising

intestinal barrier function.

This controlling effect of IBD fibroblasts on barrier function when combined with healthy

epithelium was also accompanied by increased production of multiple inflammatory cytokines

and chemokines including IL-6, MCP-1 (**Fig. 4B**), IL-8, CXCL-1, LIF, IL-21, PlGF-1, and MIP-1b

(**Extended Data Fig. 11A**) relative to chips lined by healthy fibroblasts and epithelium or healthy

epithelium alone. However, the IBD epithelium appeared to constitutively express high levels of

all these cytokines regardless of whether or not IBD fibroblasts were present or they were

replaced with healthy fibroblasts, except for production of IL-6 and MCP-1 that were further

enhanced by the presence of the IBD stroma (**Fig. 4C** and **Extended Data Fig. 11B**). As these

two cytokines are known to promote monocyte infiltration into stroma from the vascular system

and their differentiation to macrophages cells[32], we perfused human peripheral blood

mononuclear cells (PBMCs) through the basal channel of the Colon Chips. We found that more

PBMCs adhered to the stroma and migrated to the epithelial channel in the IBD Chips

compared to Healthy Chips (**Fig. 4D**). While application of peristalsis-like deformations did not

alter PBMC adhesion to the stroma in the basal channel, it significantly enhanced the migration

of these cells to the epithelium in the apical channel, but only in IBD Chips (**Fig. 4E**). However,

when we carried out a similar study in a heterotypic tissue recombinant chip containing IBD

epithelium with healthy fibroblasts, PBMC recruitment and migration were suppressed and

reverted to the low levels observed in Healthy Chips (**Fig. 4D,E**). This finding correlates well

with transcriptomic analysis, which revealed that multiple surface receptors for immune cell

adhesion are expressed at higher levels in fibroblasts and epithelium in IBD Chips versus

Healthy Chips (**Extended Data Fig. 11C**). IBD Chips co-cultured with PBMCs also showed

increased production of IL-6 and IL-8 in both their apical and basal channels, whereas this was

not observed when Healthy Chips (**Extended Data Fig. 11D**).

Modeling Early Cancer Progression in Human IBD Chips

Patients with IBD have a higher incidence of colorectal cancer formation[33] and this also

has been demonstrated in animal IBD models by exposing them to the carcinogen ENU[34].

When we exposed Healthy and IBD Chips created with cells from multiple different donors to

ENU (10 μg/ml) for 3 weeks, we observed a decrease in the height of crypt-like structures (**Fig.**

5A,B) and an increase in barrier permeability (**Fig. 5C**) in both in healthy and IBD Chips.

However, ENU had a much greater impact on inflammatory cytokine secretion in the IBD Chips

(**Fig. 5D**) and it resulted in a greater reduction of E-cadherin expression in IBD Chips versus

Healthy Chips, which was accompanied by a concomitant increase in β-catenin translocation to

the nucleus (**Fig. 5E,F**). Similar activation of the β-catenin signaling pathway has previously

been shown to be associated with colorectal cancer progression[35]. In addition, ENU treatment

promoted enlargement of epithelial nuclei and a decrease in their roundness, which are also

known to accompany early carcinogenesis[36]. Importantly, shallow pass genome sequencing

revealed increased gene mutations and duplication in IBD Chips, but not in Healthy Chips (**Fig.**

5G). Interestingly, the CD chips exhibited a higher level of gene amplification than chips lined

with cells from UC patients, and an existing mutation in one CD patient was further amplified

after ENU exposure.

We then investigated whether the fibroblast phenotype influences the propensity for

cancer formation following ENU exposure in healthy versus IBD epithelium cultured on-chip.

CEACAM5 is an early stage colorectal cancer (CRC) marker[37], which is expressed in only CRC

tissues and not in healthy and IBD intestinal epithelium in vivo (**Extended Figure 12A**). When

we analyzed its expression in epithelium in our heterotypic and homotypic tissue recombinants

on-chip, we found that neither healthy nor IBD epithelium expressed CEACAM5 on-chip under

baseline conditions without ENU exposure (**Extended Data Fig. 12B).** Importantly, healthy

epithelium exposed to ENU expressed CECAM5, but only when cultured with IBD fibroblasts

(**Fig. 5H and Extended Data Fig.12C**). The presence of IBD fibroblasts also enhanced

expression of CEACAM5 in IBD epithelium when exposed to ENU, although lower levels of

CEACAM5 expression were even observed when IBD epithelium was cultured alone or with

healthy fibroblasts. A greater reduction in E-cadherin expression (**Extended Data Fig. 12D,E**),

along with β-catenin translocation to the nucleus also were seen in IBD epithelium cultured with

IBD fibroblasts when exposed to ENU (**Extended Data Fig. 12F**). Taken together, these data

show that IBD fibroblasts play a significant role in driving a increased propensity for cancer

initiation in intestinal epithelium.

Discussion

Taken together, these findings show that human Colon Chips created with primary

patient-derived colonic epithelium and fibroblasts from both healthy and IBD patients

recapitulate many features of their respective healthy and diseased phenotypes that are

observed in vivo. Based on its synthetic nature, this model enabled exploration of the roles of

stromal fibroblasts, epithelium, and immune cells, as well as fluid flow and peristalsis-like

mechanical deformations in the etiology of this disease. Importantly, our results revealed that

the stroma is a key driver of the IBD phenotype as it is appears to drive effects on intestinal

permeability, inflammation, and immune cell infiltration in human intestinal tissues. The finding

that IBD stromal fibroblasts respond differently to physiological peristalsis motions than healthy

fibroblasts and exhibits enhanced inflammation and fibrotic responses while fluid flow was

maintained constant also suggests that physiological mechanical deformations of intestine

during early stages of IBD development may feed back to further enhance inflammation and

fibrosis thereby accelerating disease progression. In addition, we found that ovarian hormones

influence the IBD phenotype directly by targeting the intestinal stroma and enhancing

inflammation and fibrosis. .

Finally, we demonstrated that the human IBD Chips also exhibit an enhanced sensitivity

to a carcinogen and undergo changes that underlie early stages of carcinogenesis in vitro,

which is again consistent with the finding that IBD patients have an increased propensity to

develop colorectal cancers. Our finding that intestinal stromal fibroblasts influence immune cell

trafficking is consistent with a past study in which knock out of genes expressed in an

inflammatory subset of fibroblasts produced a similar effect in a mice DSS colitis model[12].

These results raise the possibility that human Colon Chips could be used as a preclinical model

with IBD patient cells to study the effects of emerging immune cell targeting therapies (e.g., anti-

integrin $\alpha 4\beta 7$ to suppress infiltration of circulating T-cells) on IBD stroma versus epithelium and

to determine their potential efficacy in a patient-specific manner[39]. In addition, this work might

serve as inspiration to develop other stroma-targeted therapies given our findings that the

stroma is a key driver of the IBD state in both females and males. The stroma also plays a

critical role in intestinal homeostasis by supporting the intestinal stem cell niche growth and

modulating immune responses, as well as protection against microbiota[40].

Another novel feature of this study is its relevance for Women's Health. Female IBD patients

can experienced loose and increased stools during the menstrual cycle as well as greater fetal

complications during pregnancy [31,41]. However, it has not been possible in the past to explore

whether or not these symptoms are the result of direct effects of female hormones on intestinal

tissues. This is because female hormone research is challenging using animals. For example,

mice that are often used for women's health research[42] do not menstruate like humans do (e.g.,

they undergo an estrous cycle) and their immune responses different significantly from human[43].

Because biopsy collection during menstruation or pregnancy is not easily done in a clinical

setting, it is also challenging to understand the biological basis for clinical symptoms observed

in female IBD patients. Another advantage of our model is that we can measure the direct

effects of these hormones on healthy versus IBD intestinal tissues. Our finding that pregancy

hormones directly enhance inflammation and fibrosis in Colon Chips, particularly in female IBD

Chips could be at least in part explain the exacerbation of IBD symptoms symptoms observed

during pregnancy in 30-35% of female IBD patients[38]. We also observed an increase in the

height of crypt-like structures in Colon Chips as a result of exposure to pregnancy-associated

hormones both in healthy and IBD chips. A similar increase in villi height was observed in the

small intestine of healthy pregnant mice, and this increased surface area is thought to support

increased nutrient absorption for the fetus.[44,45] However, our results showing that the colonic

epithelium undergo similar expansion in response to pregnancy hormones in both healthy and

IBD tissues suggests that this may not be limited to nutrient absorption, and also include water

and electrolyte reabsorption. Thus, these data provide new insights into how female hormones

influence intestinal physiology in both healthy and IBD patients.

In addition to increased inflammation and decreased mucus production, lack of intestinal

motion due to fibrosis is a hallmark of IBD; however, it has not been previously possible to

explore whether peristalsis plays a role in earlier stages of IBD progression. We found that

peristalsis-like mechanical deformations increased production of the protective mucus layer in

Healthy Chips, but less so in IBD Chips, and that these mechanical cues also enhanced

inflammation and fibrosis, but only in IBD Chips. This suggests that persistence of physiological

peristalsis during early stages of inflammation may promote progression of IBD, and that fibrosis

and resultant suppression of peristalsis likely occur at a later stage in this process. This may, in

part, occur because the IBD tissues lose their ability to maintain the mucus barrier that protects

against dysbiotic microbiome and pathogens that are known to be enriched in the microbiome of

IBD patients, such as *Ruminococcus* family members that degrade mucus[46]. This could then

lead to more inflammation and a positive feedback loop characterized by enhanced sensitivity to

these mechanical deformations resulting in greater increases in inflammation, ECM

accumulation, and fibrosis at later stages of the disease, which stiffens the mucosa and

physically restricts tissue distension.[41]

Chronic inflammation in patients with IBD is known to be a risk factor for increased cancer

formation. Importantly, our results show that human IBD tissues do indeed exhibit an enhanced

sensitivity to a carcinogen (ENU) compared to Healthy colon tissues on-chip, as indicated by

crypt blunting, loss of adherent junctions, overexpression of the early stage CRC marker

CEACAM5, and localization of β-catenin to the nucleus as seen in IBD patient tissues that

progress to colorectal cancer[47]. Importantly, we also observed a greatly increased inflammatory

response as well as accelerated development of cancer-associated mutations and

chromosomal amplifications in IBD Chips but not Healthy Chips, even though immune cells

were not present. While similar effects have been observed after exposure to ENU in a murine

intestine model [48], this to our knowledge is the first demonstration of early cancer progression in

a preclinical *human* IBD model. Although it has been believed that both CD and UC patients

carry a similarly high risk of cancer progression [49], many CD patients undergo colectomy early

in the course of the disease to alleviate persistent symptoms[50], and this effectively eliminates

their risk of developing colorectal cancer.[59] Interestingly, although our sampling was small, we

found that ENU induced greater gene and chromosomal aberrations in CD patient tissues than

in UC patient chips, suggesting that they might exhibit a greater susceptibility to carcinogens.

More importantly, use of Organ Chip technology enabled us to create tissue recombinant

models, which revealed that IBD fibroblasts play a central role in driving this increased

propensity for cancer formation. This result is consistent with finding that cancer-associated

fibroblasts also promote a dysplastic transition in metaplastic gastric epithelial cells.[51] This is a

finding which should be followed up in clinical studies in the future.

The incidence of IBD is anticipated to increase in the upcoming years. Limitations in the

ability of in vivo models to represent human IBD physiology are evident, as the most commonly

used anti-TNF and anti-IL-12/23p40 antibodies, which benefit patients with IBD, are generally

not effective in chemically-induced colitis models[52]. The need for modeling IBD using Organ

Chip technology also has been acknowledged by leading IBD organizations, such as the

Crohn's and Colitis Foundation[53]. Therefore, we believe this novel microfluidic disease model

brings important opportunities for IBD treatment, management, and drug development. As we

can analyze outflows from the epithelial and stromal compartments separately and through use

of tissue recombinants, this method also may facilitate discovery of potential stool and blood

biomarkers of IBD progression and cancer risk as well as response to therapy. Use of tissue

recombinants is a powerful method for analyzing epithelial-mesenchymal interactions in

commonly used developmental biology research, which as we show here also may be applied

to confront similar questions relating to human epithelial-stromal interactions, which are

challenging to address in vivo. In addition to enabling study of the effects of female hormones

on IBD, and it also could allow investigation of other IBD subcategories, including very early

onset (VEO-IBD), adolescent IBD, and genetic forms of the disease by lining chips with relevant

patient cells.

While this model recapitulates IBD-associated features observed in the human colon,

other intestinal regions such as the ileum, duodenum, jejunum, and rectum, could also be

modeled using IBD tissues collected from these sites. Modeling these additional regions,

particularly the small intestine, would be valuable for investigating absorption and metabolism-

related complications in IBD. Notably, Organ Chip technology has already enabled the modeling

of these regions using tissues collected from healthy patients[54–56] . Diet can also influence

exacerbation of colitis and a small intestine IBD model could be beneficial to investigate diet-

associated features in IBD, given that short chain fatty acids (SCFAs), such as butyrate,

produced by healthy microbiome can affect IBD remission[57,58]. While we modeled epithelial-

stromal interactions in IBD chips, other IBD specific features. such as ileitis-associated fat

creeping. can be modeled as well by including adipocytes in the model. In this study, we co-

cultured immune cells alongside disease-specific epithelial cells and fibroblasts. This capability

can enable evaluation of immune cell-targeting therapeutics, such as α4β7, TL1A, JAK, TNF-α

and IL-23 inhibitors[59], alone or when combined with each other for their potential downstream

effects on mucosal tissues and associated complications. Particularly fibrosis has been an

unmet challenge in management of IBD in patients as well as other fibrotic diseases (e.g. cystic

fibrosis, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis and idiopathic pulmonary

fibrosis). Finally, given the synthetic nature of the model and as living gut microbiome can be

co-cultured in these Intestine Chips for extended times[54,60], this experimental system also may

be used to study how other environmental factors (such as pathogens) contribute to

development of the IBD phenotype in the future.

Methods

Acquisition of human colon tissue and cells

Healthy colon tissue samples were collected from macroscopically grossly unaffected

regions of the colon of de-identified healthy adult patients undergoing endoscopy for non-IBD

related complaints, such as diverticulitis. IBD tissue samples were collected from tissue

resections from IBD patients with either CD disease or Ulcerative Colitis. Informed consent and

developmentally appropriate assent were obtained at Massachusetts General Hospital and

McGill University Health Centre from the donors. All methods were performed in accordance

with the Institutional Review Board of Massachusetts General Hospital approval (protocol

number IRB-2015P001859) and McGill University Health Centre (protocol number REB-2007-

856). We generated epithelium-derived organoids (colonoids) that were cultured in Matrigel

using published methods[13,54]and isolated stromal fibroblasts from the same IBD tissues from 3

CD and 4 UC patients, which were cultured in fibroblast medium (FM, CC-3132, Lonza, MA) in

75 cm^2 flasks (3531135, Falcon, Durham, NC) with Primocin (100 μg/ml) replaing the GA

supplement. Healthy colonoids and fibroblasts were isolated from areas with normal histology

adjacent to regions of diverticulitis from 4 otherwise healthy patients (**Supplementary Table 1**).

The donor cells used across the experiments were provided in **Supplementary Table 2**. All

reagents and resources were provided in **Supplementary Table 3**.

Human Colon Chip Cultures

Our methods for creating and culturing human Colon Chips lined by primary intestinal

organoid-derived epithelium using commercially available Organ Chip Devices (Basic Research

Kit; Emulate Inc.) have been described previously[13,61] and are described in greater detail in

Supplementary Materials. Colonoids cultured were released from Matrigel and fragmented by

treatment with TrypLE Express Enzyme (12605010; Thermo Fisher Scientific), before being

seeded in the apical channel of the 2-channel Organ Chip devices and incubated overnight at

37° C under 5% CO_2 to promote adhesion. One day later, channels were washed with

Expansion Medium (EM) to remove unattached cells, and then perfused with EM (60 µL/hr). At

this time, the cultured fibroblasts were detached enzymatically and seeded in EM in the basal

channel for 2 h under static conditions to promote adhesion. After washing, EM was then

perfused through both channels at 60 μL/h. After 3 days of co-culture during which both

epithelial and fibroblast monolayers were established, EM perfused through the apical channel

was changed to Hank's balanced salt solution (HBSS) with calcium and magnesium (21-023-cv;

Corning) supplemented with 100 mg/mL Primocin (ant-pm-1; InvivoGen) while EM remained

flowing through the basal channel. For experiments exploring the role of physiological

peristalsis-like motions, cyclic mechanical strain (10% Strain 0.15 Hz) was applied to the tissues

by applying cyclic suction to side chambers of the flexible device[54,61] for 2 weeks after seeding.

Methods for morphological analysis, cytokine quantification, flow cytometry, transcriptional

analysis, and atomic force microscopy can be found in **Supplementary Information**.

Maternal Hormone Treatment

Established Healthy and IBD Colon Chips were exposed to different combinations of

hormones from basal channel to recapitulate either the menstrual cycle or first trimester of

pregnancy. Chips were treated with 17β-estradiol (E2, 10 nM, Sigma, E4389) for 3 days before

being exposed to medroxyprogesterone 17-acetate (MPA, 1 μM, Sigma, 46412-250MG) for an

additional 4 days to mimic the menstrual period of the cycle. Chips perfused for 3 days with E2

were then treated with E2, MPA, Prolactin (PRL, 20 ng/mL, VWR, 10770-682), Human Placental

Lactogen/CSH1 (hPL, 20 ng/ml, R&D, 5757-PL), and Human Chorionic Gonadotropin (HCG, 1

μg/mL, VWR, IC0219859110) for 4 days to recapitulate the first trimester of pregnancy as

described previously[62,63].

Immune Cell Recruitment Assay

Colon Chips were cultured for 2 weeks before human peripheral blood mononuclear

cells (PBMCs) were added to the cultures for studies on immune cell adhesion and migration.

PBMCs were collected from anonymous donors undergoing stem cell mobilization at the

Massachusetts General Hospital (MGH) under Institutional Review Board approved protocol

#2015P001859. PBMCs were freshly isolated by density centrifugation using the Lymphoprep

protocol (StemCell Technologies, #07801), resuspended in 10 ml of DMEM containing 10%

FBS(10082-147) and 1% Penicillin-Streptomycin (P4333-100ML), and labeled with 10 μl of

CellTracker Deep Red at a final concentration of 10 μM (Invitrogen, #C34565) for 20 minutes at

37°C. The labeled cells were centrifuged and resuspended to a concentration of 5×10^7 cells/ml

and 25 μl of the PBMC suspension was added to the lower channel (see **Supplementary**

Information for more details).

Analysis of effects of carcinogen exposure

To explore if the chip models can be used to study the effects of intestinal tissue to

carcinogen exposure in vitro, Healthy and IBD Colon Chips were exposed to 10 μg/mL of N-

ethyl-N-nitrosourea (ENU, Millipore Sigma, N8509), which was flowed through both the apical

and basal channels at 60 μL/hr. Chips were harvested for DNA isolation three weeks after ENU

exposure. Briefly, chips were washed with DPBS (-/-) and incubated with TrypLE consisting of 2

mg/mL collagenase-I (Thermo Fisher Scientific, 17100-017) and 10 μM Y-27632 (Y0503;

Sigma-Aldrich, St. Louis, MO) at 37°C for 1 h. Single cells were washed with DPBS (-/-) and

DNA was isolated by following the manufacturer's protocol (Qiagen Micro DNA isolation kit, Cat:

56304 Qiagen, Germany). Shallow whole genome sequencing was performed in two batches

using different methods (see **Supplementary Information**). The raw sequence reads were

mapped to *Homo sapiens* GRCh38 with Burrows-Wheeler Alignment Tool v0.7.17[64]. Reads with

a mapping quality of less than 37 were removed from further analysis. The PCR duplicates and

base quality recalibration were subsequently carried out using Genome Analysis Toolkit (GATK)

v4.4.0[65] and Picard v2.27.5. The copy number of the genome was then estimated and profiled

with ACE v3.16[66] and QDNAseq v1.35.0 R package[67] using 100 Mb fixed-sized bins.

Statistical Analysis

Data in all graphs are expressed as mean ± standard deviation (SD) and significant

differences between multiple groups were determined using an unpaired Students t-test, one-

way analysis of variance (ANOVA) or two-way ANOVA with Tukey test for correction unless

otherwise indicated in the figure legends. $P<0.05$ was considered significant. Data were

analyzed using GraphPad Prism 8 software (GraphPad Software, San Diego, CA).

Acknowledgement

Development Fellowship to A.Ö. We thank Harvard Digestive Diseases Center Organoid Core

for providing L-WRN conditioned media (P30DK034854).

Contributions

A.O., S.H. and D.E.I designed the research; A.O., G.E.M, R.R.P. A.S. K. C., E. C., J.P.

performed the experiments; A.O., G.E.M., R.R.P. A.S., K.C., E.C. analyzed and interpreted the

data; A.O. and G.E.M. established healthy and IBD human organoid and fibroblast biobanks; V.

H., M. S. and A.O. performed bioinformatic analysis; D.B.C., L.E.F., R.R., L.B. provided the

clinical samples; A.O. and D.E.I. acquired the funding; A.O. wrote the articled with input from

G.G., S.H. and D.E.I.; and all authors reviewed, discussed and edited the manuscript.

Data and code availability

502 Data that support the findings of this study are available within the paper and its

503 Supplementary Information files. The RNA sequencing data have been deposited in the Gene

504 Expression Omnibus (GEO) with the accession code GSE277964. All data reported in this study

505 are available in the Source Data files. Any other material including the R code used for data

506 analysis is available upon reasonable request.

Competing interests

508 D.E.I. holds equity in Emulate, chairs its scientific advisory board and is a member of its board

509 of directors. The other authors declare no competing interests.

References

1.   Friedrich, M. *et al.* IL-1-driven stromal–neutrophil interactions define a subset of patients

with inflammatory bowel disease that does not respond to therapies. *Nat Med* **27**, 1970–

1981 (2021).

2.   Goodman, W. A., Erkkila, I. P. & Pizarro, T. T. Sex matters: impact on pathogenesis,

presentation and treatment of inflammatory bowel disease. *Nature Reviews*

Gastroenterology & Hepatology 2020 17:12 **17**, 740–754 (2020).

3.   Watermeyer, G. Pregnancy and inflammatory bowel disease. *South African*

Gastroenterology Review **5**, 4–6 (2007).

4.   Sarvestani, S. K. *et al.* Cancer-predicting transcriptomic and epigenetic signatures
revealed for ulcerative colitis in patient-derived epithelial organoids. *Oncotarget* **9**,
28717–28730 (2018).

5.   Ingber, D. E. Cancer as a disease of epithelial–mesenchymal interactions and
extracellular matrix regulation. *Differentiation* **70**, 547–560 (2002).

6.   Smillie, C. S. *et al.* Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative
Colitis. *Cell* **178**, 714-730.e22 (2019).

7.   Rieder, F. & Fiocchi, C. Intestinal fibrosis in IBD - A dynamic, multifactorial process. *Nat*
Rev Gastroenterol Hepatol **6**, 228–235 (2009).

8.   Guglielmo, F. F. *et al.* Identifying decreased peristalsis of abnormal small bowel
segments in Crohn's disease using cine MR enterography: the frozen bowel sign. *Abdom*
Imaging **40**, 1150–1156 (2015).

9.   Joshi, A., Soni, A. & Acharya, S. In vitro models and ex vivo systems used in
inflammatory bowel disease. *In vitro models 2022 1:3* **1**, 213–227 (2022).

10.   Özkan, A., LoGrande, N. T., Feitor, J. F., Goyal, G. & Ingber, D. E. Intestinal organ chips
for disease modelling and personalized medicine. *Nat Rev Gastroenterol Hepatol* 1–23
(2024) doi:10.1038/s41575-024-00968-3.

11.   Ingber, D. E. Human organs-on-chips for disease modelling, drug development and
personalized medicine. *Nat Rev Genet* **23**, 467–491 (2022).

12.   Gustafsson, J. K. & Johansson, M. E. V. The role of goblet cells and mucus in intestinal
homeostasis. *Nat Rev Gastroenterol Hepatol* **19**, 785–803 (2022).

13.   Sontheimer-Phelps, A. *et al.* Human Colon-on-a-Chip Enables Continuous In Vitro
Analysis of Colon Mucus Layer Accumulation and Physiology. *Cmgh* **9**, 507–526 (2020).

14.   Tovaglieri, A. *et al.* Species-specific enhancement of enterohemorrhagic E. coli
pathogenesis mediated by microbiome metabolites. *Microbiome* **7**, 1–21 (2019).

15.   Chan, C. W. M. *et al.* Gastrointestinal differentiation marker Cytokeratin 20 is regulated
by homeobox gene CDX. *Proc Natl Acad Sci U S A* **106**, 1936–1941 (2009).

16.   West, N. R. *et al.* Oncostatin M drives intestinal inflammation and predicts response to
tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease.
Nat Med **23**, 579–589 (2017).

17.   Wu, J. *et al.* Therapeutic targeting of vimentin by ALD-R491 impacts multiple pathogenic
processes to attenuate acute and chronic colitis in mice. *Biomedicine & Pharmacotherapy*
168, 115648 (2023).

18.   Torres, J. *et al.* Serum Biomarkers Identify Patients Who Will Develop Inflammatory
Bowel Diseases Up to 5 Years Before Diagnosis. *Gastroenterology* **159**, 96–104 (2020).
19.   Danese, S., Sans, M. & Fiocchi, C. The CD40/CD40L costimulatory pathway in
inflammatory bowel disease. *Gut* **53**, 1035 (2004).
20.   Liu, Z. *et al.* Genetic architecture of the inflammatory bowel diseases across East Asian
and European ancestries. *Nat Genet* **55**, 796 (2023).
21.   Tian, T., Wang, Z. & Zhang, J. Pathomechanisms of Oxidative Stress in Inflammatory
Bowel Disease and Potential Antioxidant Therapies. *Oxid Med Cell Longev* **2017**,
4535194 (2017).
22.   Stokkers, P. C. F., Reitsma, P. H., Tytgat, G. N. J. & Van Deventer, S. J. H. HLA-DR and
-DQ phenotypes in inflammatory bowel disease: a meta-analysis. *Gut* **45**, 395 (1999).
23.   Yu, W. *et al.* Association of a Nkx2-3 polymorphism with Crohn's disease and expression
of Nkx2-3 is up-regulated in B cell lines and intestinal tissues with Crohn's disease. *J*
Crohns Colitis **3**, 189–195 (2009).
24.   WO2019018571A1 - Methods and uses of inflammatory bowel disease biomarkers -
Google Patents. https://patents.google.com/patent/WO2019018571A1/en.
25.   Srivastava, M., Zurakowski, D., Cheifetz, P., Leichtner, A. & Bousvaros, A. Elevated
Serum Hepatocyte Growth Factor in Children and Young Adults With Inflammatory Bowel
Disease. *J Pediatr Gastroenterol Nutr* **33**, 548–553 (2001).
26.   Cheng, C. *et al.* Identification of differentially expressed genes, associated functional
terms pathways, and candidate diagnostic biomarkers in inflammatory bowel diseases by
bioinformatics analysis. *Exp Ther Med* **18**, 278–288 (2019).
27.   Wilson, A. *et al.* Crohn's Disease Is Associated with Decreased CYP3A4 and P-
Glycoprotein Protein Expression. *Mol Pharm* **16**, 4059–4064 (2019).
28.   Sen, A. & Stark, H. Role of cytochrome P450 polymorphisms and functions in
development of ulcerative colitis. *World J Gastroenterol* **25**, 2846 (2019).
29.   Dubuquoy, L. *et al.* PPARγ as a new therapeutic target in inflammatory bowel diseases.
Gut **55**, 1341 (2006).
30.   Ashton, J. J. *et al.* Deleterious Genetic Variation Across the NOD Signaling Pathway Is
Associated With Reduced NFKB Signaling Transcription and Upregulation of Alternative
Inflammatory Transcripts in Pediatric Inflammatory Bowel Disease. *Inflamm Bowel Dis*
28, 912–922 (2022).
31.   Lim, S. M. *et al.* The effect of the menstrual cycle on inflammatory bowel disease: A
prospective study. *Gut Liver* **7**, 51–57 (2013).

32.   Chomarat, P., Banchereau, J., Davoust, J. & Karolina Palucka, A. IL-6 switches the
587   differentiation of monocytes from dendritic cells to macrophages. *Nature Immunology*
588   *2000 1:6* **1**, 510–514 (2000).

589   33.   Murphy, C. C. & Zaki, T. A. Changing epidemiology of colorectal cancer — birth cohort
590   effects and emerging risk factors. *Nat Rev Gastroenterol Hepatol* **21**, 25–34 (2023).

591   34.   Schmitt, M. & Greten, F. R. The inflammatory pathogenesis of colorectal cancer. *Nat Rev*
592   *Immunol* **21**, 653–667 (2021).

593   35.   Herzig, M., Savarese, F., Novatchkova, M., Semb, H. & Christofori, G. Tumor progression
594   induced by the loss of E-cadherin independent of β-catenin/Tcf-mediated Wnt signaling.
595   *Oncogene* **26**, 2290–2298 (2007).

596   36.   Zink, D., Fischer, A. H. & Nickerson, J. A. Nuclear structure in cancer cells. *Nature*
597   *Reviews Cancer 2004 4:9* **4**, 677–687 (2004).

598   37.   Michl, J., White, B., Monterisi, S., Bodmer, W. F. & Swietach, P. Phenotypic screen of
599   sixty-eight colorectal cancer cell lines identifies CEACAM6 and CEACAM5 as markers of
600   acid resistance. *Proc Natl Acad Sci U S A* **121**, e2319055121 (2024).

601   38.   Goodman, W. A., Erkkila, I. P. & Pizarro, T. T. Sex matters: impact on pathogenesis,
602   presentation and treatment of inflammatory bowel disease. *Nature Reviews*
603   *Gastroenterology & Hepatology 2020 17:12* **17**, 740–754 (2020).

604   39.   D'Alessio, S. *et al.* Revisiting fibrosis in inflammatory bowel disease: the gut thickens. *Nat*
605   *Rev Gastroenterol Hepatol* **19**, 169–184 (2022).

606   40.   Ryan, F. J. *et al.* Colonic microbiota is associated with inflammation and host epigenomic
607   alterations in inflammatory bowel disease. *Nat Commun* **11**, 1–12 (2020).

608   41.   Mendelson, S., Anbukkarasu, P., Cassisi, J. E. & Zaman, W. Gastrointestinal functioning
609   and menstrual cycle phase in emerging young adult women: a cross-sectional study.
610   *BMC Gastroenterol* **23**, 1–10 (2023).

611   42.   Bellofiore, N., Ellery, S., Mamrot, J., … D. W.-A. journal of & 2017, undefined. First
612   evidence of a menstruating rodent: the spiny mouse (Acomys cahirinus). *Elsevier*.

613   43.   Bellofiore, N., Cousins, F., Temple-Smith, P., Dickinson, H. & Evans, J. A missing piece:
614   the spiny mouse and the puzzle of menstruating species. *J Mol Endocrinol* **61**, R25–R41
615   (2018).

616   44.   Onji, M. *et al.* RANK drives structured intestinal epithelial expansion during pregnancy.
617   *Nature 2024 637:8044* **637**, 156–166 (2024).

45.   Ameku, T. *et al.* Growth of the maternal intestine during reproduction. *Cell* **0**, (2025).

46.   Paone, P. & Cani, P. D. Mucus barrier, mucins and gut microbiota: the expected slimy
partners? *Gut* **69**, 2232 (2020).

47.   Aust, D. E. *et al.* Altered distribution of β-catenin, and its binding proteins E-cadherin and
APC, in ulcerative colitis-related colorectal cancers. *Modern Pathology* **14**, 29–39 (2001).

48.   Winton, D. J. & Ponder, B. A. J. Stem-cell organization in mouse small intestine. *Proc Biol*
Sci **241**, 13–18 (1990).

49.   Winawer, S. J. *et al.* Colorectal Cancer Screening: Clinical Guidelines and Rationale The
Adenoma-Carcinoma Sequence. *Gastroenterology* **112**, 594–642 (1997).

50.   Gillen, C. D., Walmsley, R. S., Prior, P., Andrews, H. A. & Allan, R. N. Ulcerative colitis
and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. *Gut*
35, 1590 (1994).

51.   Lee, S. H. *et al.* Apposition of Fibroblasts With Metaplastic Gastric Cells Promotes
Dysplastic Transition. *Gastroenterology* **165**, 374–390 (2023).

52.   Pizarro, T. T. *et al.* Challenges in IBD Research: Preclinical Human IBD Mechanisms.
Inflamm Bowel Dis **25**, S5–S12 (2019).

53.   Heller, C. A. *et al.* Challenges in IBD Research. *Inflamm Bowel Dis* **25**, S31–S39 (2019).

54.   Jalili-Firoozinezhad, S. *et al.* A complex human gut microbiome cultured in an anaerobic
intestine-on-a-chip. *Nat Biomed Eng* **3**, 520–531 (2019).

55.   Kasendra, M. *et al.* Development of a primary human Small Intestine-on-a-Chip using
biopsy-derived organoids. *Sci Rep* **8**, 1–14 (2018).

56.   Bein, A. *et al.* Nutritional deficiency in an intestine-on-a-chip recapitulates injury hallmarks
associated with environmental enteric dysfunction. *Nat Biomed Eng* **6**, 1236–1247
(2022).

57.   Aden, K. *et al.* BASIC AND TRANSLATIONAL-ALIMENTARY TRACT Metabolic
Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists
in Patients With Inflammatory Bowel Diseases. (2019) doi:10.1053/j.gastro.2019.07.025.

58.   Kennedy, M. S. *et al.* Diet outperforms microbial transplant to drive microbiome recovery
in mice. *Nature 2025* 1–9 (2025) doi:10.1038/s41586-025-08937-9.

59.   Vieujean, S. *et al.* Understanding the therapeutic toolkit for inflammatory bowel disease.
Nature Reviews Gastroenterology & Hepatology 2025 22:6 **22**, 371–394 (2025).

60.   Kim, H. J., Huh, D., Hamilton, G. & Ingber, D. E. Human gut-on-a-chip inhabited by
microbial flora that experiences intestinal peristalsis-like motions and flow. *Lab Chip* **12**,
2165–2174 (2012).

61.   Tovaglieri, A. *et al.* Species-specific enhancement of enterohemorrhagic E. coli
pathogenesis mediated by microbiome metabolites. *Microbiome* **7**, 1–21 (2019).

62.   Turco, M. Y. *et al.* Long-term, hormone-responsive organoid cultures of human
endometrium in a chemically defined medium. *Nat Cell Biol* **19**, 568–577 (2017).

63.   Gnecco, J. S. *et al.* Organoid co-culture model of the human endometrium in a fully
synthetic extracellular matrix enables the study of epithelial-stromal crosstalk. *Med* **4**,
554-579.e9 (2023).

64.   Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler
transform. *Bioinformatics* **25**, 1754–1760 (2009).

65.   Genomics in the Cloud: Using Docker, GATK, and WDL in Terra - Geraldine A. Van der
Auwera, Brian D. O'Connor - Google Books.
https://books.google.com/books?hl=en&lr=&id=vsXaDwAAQBAJ&oi=fnd&pg=PP1&dq=V
an+der+Auwera+GA+%26+O%27Connor+BD.+(2020).+Genomics+in+the+Cloud:+Using
+Docker,+GATK,+and+WDL+in+Terra+(1st+Edition).+O%27Reilly+Media.&ots=5lcr0E-
qna&sig=43MTbQQNO_yexxB7NxDgVt88kOk#v=onepage&q&f=false.

66.   Poell, J. B. *et al.* ACE: absolute copy number estimation from low-coverage whole-
genome sequencing data. *Bioinformatics* **35**, 2847–2849 (2019).

67.   Scheinin, I. *et al.* DNA copy number analysis of fresh and formalin-fixed specimens by
shallow whole-genome sequencing with identification and exclusion of problematic
regions in the genome assembly. *Genome Res* **24**, 2022–2032 (2014).

Figure Legends

Figure 1: Primary human Colon Chips generated with epithelium and fibroblasts

isolated from Healthy and IBD patient samples. A) Photograph of the commercially available

Organ Chip device (left) and a cross-sectional illustration of the epithelial-stromal tissue

interface (right) formed with patient-derived cells, which is composed of a fibroblast rich stroma

that is perfused with medium to mimic interstitial fluid flow separated by a flexible, porous, ECM-

coated membrane from a colon epithelium above. The epithelium, which is composed of

absorptive cells and Goblet cells, secretes a thick mucus layer into the lumen of the apical

channel that also experiences fluid flow. The entire tissue-tissue interface can be stretched and

relaxed rhythmically to mimic peristalsis-like motions by applying cyclic suction to hollow side

chambers in the flexible device (not shown). **B)** Height of crypts formed in Colon Chips

measured at 11 days. Numbers indicate P values between compared groups, as determined by

one-way ANOVA test (n=3 Healthy, green; 2 CD, magenta; and 2 UC, cyan). **C)** Representative

bright field microscopic images of Healthy and IBD Chips created with cells from CD or UC

patients viewed from above on day 3, 7, and 11. A functional epithelial monolayer progressively

accumulated mucus, which appears as opaque blackened fuzzy material, in the apical channel

of all chips over the 11 day time course; however, mucus accumulation was suppressed in the

IBD Chips with the UC Chips displaying a greater reduction (bar, 500 μm). **D)** Brightfield image

of vertical cross-sections through healthy and IBD Colon chips showing that the crypt-like

epithelial structures are shorter in the CD and UC Colon Chips (bar, 100 μm). **E)** Histological

H&E stained vertical cross-sections through healthy and IBD Colon chips confirming the

presence of columnar colon epithelium containing goblet cells in healthy epithelium, and a

significant reduction in the height of the epithelial monolayer with reduced numbers of goblet

cells in the IBD Chips (bar, 50 μm). **F)** Immunofluorescence microscopic views showing

distribution of SOX9 and CK20 in crypts in the colon epithelium of Healthy and IBD Chips (bar,

50 μm). **G**) Inflammatory cytokine protein levels measured in the basal outflows of Healthy (H)

and IBD Chips on culture day 11 (n = 3-5 chips/ condition; chips were created with cells from 3

healthy (green), 2 CD (magenta), and 2 UC (cyan) patient donors, with each symbol represents

a chip created with cells from a different patient. Numbers indicate *P* values between compared

groups, as determined by two-tailed student's t-test. All data represent mean $\pm$ SD; *p* values are

shown in all figures. Source data and statistical tests are provided as a Source Data file.

705   **Figure 2: Peristalsis-like cyclic strain influences mucus production and fibrosis in**

Colon Chips. A) Representative side-view images microscopy of Healthy or IBD Chips with (+)

and without (-) exposure to mechanical deformations visualizing mucus layer accumulation

(white diffuse material) in Healthy Chips using dark-field microscopy. Note that limited mucus

was produced by IBD epithelium (bar, 1 mm). **B)** Quantification of the height of the mucus layer

overlying Healthy and IBD epithelium on-chip when cultured under the conditions in A. Numbers

indicate *P* values between compared groups, as determined by one-way ANOVA test. (n = 3

healthy, green; 2 CD, magenta; and 2 UC, cyan). **C)** Heat map of genes showing that

peristalsis-like mechanical stimulation (+) increases expression of genes related to mucus

production in Healthy Chips, but not IBD Chips (n = 3 healthy, 1 CD and 2 UC). **D)** Second

harmonic microscopic images of the fibroblast stroma in Healthy versus IBD Chips showing

greater collagen fibril accumulation (green) with mechanical strain (+ Strain) in both chips, and

that this response is greatly accentuated in IBD Chips (bar, 200 μm). **E)** Collagen fibril signal

intensity in the stroma of Healthy versus IBD Chips quantified in second harmonic microscopic

images. Numbers indicate *P* values between compared groups, as determined by one-way

ANOVA test (n = 3 healthy, green; 2 CD, magenta; and 2 UC, cyan). **F)** Heat map of genes

showing that peristalsis-like cyclic strain enhances expression of genes associated with fibrillar

collagen production in IBD fibroblasts, but not in healthy fibroblasts (n = 3 healthy, 1 CD and 2

UC). **G)** Heat maps of showing that cyclic strain enhances greater expression of IBD-associated

inflammatory genes in IBD Chips compared to Healthy Chips both in epithelium and fibroblasts

(n=3 Healthy, 1 CD, and 2 UC). Source data and statistical tests are provided as a Source Data

file.

727   **Figure 3: Effects of ovarian hormones in Female Colon Chips.** DIC images from

above (**A**) and vertical cross-sectional views of confocal microscopic images (**B**) of healthy and

IBD Chips 7 days post treatment with exposure to E2, E2 plus MPA, or PAH.. **A**) When viewed

from above, exposure to PAH appeared to slightly increase the density of crypt-like structures in

both healthy and IBD chips (bar, 500 µm). **B)** When viewed in vertical cross-sections, the

number and height of crypt-like structures increased when exposed to PAH as well as E2+MPA

in both Healthy and IBD Chips, although the scale of the response was much less in the IBD

Chips (bar, 100 µm; magenta: phalloidin, cyan: DAPI; dashed white line, upper surface of chip

membrane; dashed yellow line, upper luminal boundary of the crypt). **C)** Quantification of

heights of crypt-like structures in Healthy and IBD Chips in the presence or absence of different

combinations of the ovarian hormones (E2, MPA, and PAH), as indicated (n=8-12 chips of 2

healthy, 1 CD and 2 UC patients from at least 2 independent experiments). **D)** Second harmonic

microscopic images of fibrillar collagen (green) produced by fibroblasts in response to the

different hormonal conditions shown in A and B demonstrating a much greater fibrosis response

in the IBD Chips compared to Healthy when exposed to pregnancy mimiking hormone

combination (E2+MPA+PAH) (bar, 200 µm; n=4-6 chips of 1 CD, 2 UC and 2 Healthy each from

2 independent experiments). **E)** Graphs showing quantification of collagen fibril signal intensity

in the stroma of Healthy versus IBD Chips using second harmonic microscopic imaging

(numbers indicate *P* values between compared groups, as determined by one-way ANOVA test;

n=8-12 chips of 2 healthy, 1 CD and 2 UC patients from at least 2 independent experiments). **F)**

Heatmaps showing production of pro-inflammatory cytokine and chemokine proteins in apical

(epithelial) and basal (fibroblast) channels of Healthy versus IBD Chips 7 days post treatment

with different female hormone exposures, as indicated. Note that exposure to female hormones

significantly increased expression of inflammatory factors in both the epithelium and fibroblasts

in IBD Chips whereas they suppressed their production in Healthy Chips (numbers indicate

P values between compared groups, as determined by one-tailed student's t-test; all data

represent mean $\pm$ SD). Source data and statistical tests are provided as a Source Data file; *p*

values are shown in all figures.

Figure 4: Tissue recombinant chips reveal that the IBD fibroblasts drive

compromise of the permeability barrier and inflammation in the epithelium. **A)** Graphs

showing that intestinal barrier permeability to cascade blue is much higher in homotypic IBD

Chips compared to Healthy Chips and that tissue recombinants of IBD fibroblasts with healthy

(H) epithelium results in a similar high level of barrier compromise on-chip. This is not observed

in the IBD or healthy epithelium in the absence of fibroblasts or in IBD epithelium with healthy

fibroblasts. Numbers indicate *P* values between compared groups, as determined by one-way

ANOVA test (n = 3 healthy, green; 2 CD, magenta; and 2 UC, cyan). **B)** Quantification of

cytokine protein levels revealed that combination of IBD fibroblasts with healthy epithelium

results in increased production of IL-6 and MCP-1 in Colon Chips, whereas this was not seen in

healthy epithelium alone or homotypic Colon Chips. Numbers indicate *P* values between

compared groups, as determined by one-way ANOVA test (n = 3 healthy, green; 1 CD,

magenta; and 2 UC, cyan). **C)** IL-6 and MCP-1 production by IBD epithelium also required the

presence of IBD fibroblasts. Numbers indicate *P* values between compared groups, as

determined by one-way ANOVA test (n = 3 healthy, green; 1 CD, magenta; and 2 UC, cyan). **D)**

Peristalsis-like cyclic strain preferentially stimulates migration of PBMCs (magenta) from the

fibroblast stroma in the basal channel (Basal) to the epithelium in the apical channel (Apical) in

IBD Chips but not in heterotypic chips with IBD epithelium and healthy fibroblasts or in Healthy

Chips. **E)** Quantification of the results from **D** confirmed that IBD Chips exhibited higher baseline

recruitment of PBMCs to the surface of the fibroblast stroma in the basal channel and that this

was not altered by mechanical strain, whereas IBD epithelium combined with healthy stroma or

Healthy Chips only displayed significantly less PBMC recruitment. In contrast, the number of

PBMCs that migrated to the epithelium in the Apical channel more than doubled in IBD Chips

when they were exposed to peristalsis-like mechanical deformations, and overall migration of

PBMCs was minimal when IBD fibroblasts were absent. Numbers indicate P values between

compared groups, as determined by one-way ANOVA test (n = 2 healthy, green; 1 CD,

magenta; and 1 UC, cyan). Source data and statistical tests are provided as a Source Data file.

Figure 5: Exposure to carcinogen preferentially promotes mutagenesis and early

steps in carcinogenesis in IBD Chips. A) DIC images of the epithelium when viewed from

above in Healthy (H) and IBD Chips after 21 days of culture in the presence or absence of the

carcinogen (ENU) showing that undulating crypt-like structures are lost in both Healthy and IBD

Chips after exposure to ENU (bar, 500 µm). **B)** Quantification of results from **A** showing that

ENU decreases height of the epithelium in both healthy and IBD Colon Chips. Numbers indicate

P values between compared groups, as determined by one-way ANOVA test (n = 3 healthy,

green; 2 CD, magenta; and 2 UC, cyan). **C)** Epithelial barrier permeability increased as a result

of exposure to ENU in Healthy and IBD Chips. Numbers indicate P values between compared

groups, as determined by one-way ANOVA test. (n = 3 healthy, green; 2 CD, magenta; and 2

UC, cyan). **D)** Heatmaps showing inflammatory cytokine protein levels measured in outflows

from the apical channel of Healthy and IBD Chips 3 weeks post-ENU exposure. Importantly,

ENU exposure significantly increased inflammatory cytokine production in IBD Chips made with

cells from both CD and UC patients compared to healthy patients. **E)** Confocal microscopic top-

view images showing β-catenin and E-cadherin localization and nuclear staining (DAPI) in the

epithelium within Healthy and IBD Chips 3 weeks post-ENU exposure (bar, 20 µm). **F)**

Quantification of protein staining intensity and morphology reveal that ENU exposure decreases

E-cadherin levels and increases nuclear localization of β-catenin in IBD patient-derived Colon

Chips compared to Healthy Chips. ENU exposure also resulted in greater nucleus size and less

roundness. Numbers indicate P values between compared groups, as determined by Student's

t-test (n = 3 healthy, green; 2 CD, magenta; and 2 UC, cyan). **G)** Plots showing copy number

changes across all human chromosomes in Healthy and IBD Chips pre- (red) and 3 weeks post-

ENU exposure (blue). Green bars indicate amplification of gene sequences for the whole

chromosome. Each symbol represents an individual Healthy or IBD patient-derived chip. **H)**

Confocal microscopic top-view images showing early stage CRC marker, CEACAM5,

expression in healthy and IBD epithelium when they are cultured with with or without healthy

fibroblasts or IBD fibroblasts and exposed to ENU for 3 weeks. Source data and statistical tests

are provided as a Source Data file.

Fig. 1

Fig. 2

Fig. 3

Fig. 4

Fig. 5

Extended Data Fig. 1

Extended Data Fig. 2

Extended Data Fig. 3

A

B

C

D

Extended Data Fig. 4

A

B

C

D

Extended Data Fig. 6

A

Permeability (×10⁻⁶, cm/s)

Patient:	H	H	IBD	IBD
Strain:	−	+	−	+

B

GOBP INFLAMMATORY RESPONSE
+Strain vs - Strain Healthy Colon Chip (Epithelium)

Adj p-val: <0.00010
NES: 1.78

Running enrichment score

Genes ranked by log₂ fold change

GOBP INFLAMMATORY RESPONSE
+Strain vs -Strain IBD Colon Chip (Epithelium)

Adj p-val: <0.00010
NES: 2.13

Running enrichment score

Genes ranked by log₂ fold change

Extended Data Fig. 7

Extended Data Fig. 8

A

KEGG PATHWAYS IN CANCER
+Strain vs -Strain IBD Colon Chips (Epithelium)

Adj p-val: <0.00010
NES: 1.72

KEGG TOLL LIKE RECEPTOR SIGNALING PATHWAY
+Strain vs -Strain IBD Colon Chips (Epithelium)

Adj p-val: 0.00084
NES: 1.86

KEGG PPAR SIGNALING PATHWAY
+Strain vs -Strain IBD Colon Chips (Epithelium)

Adj p-val: 0.03928
NES: 1.64

GOBP VASCULATURE DEVELOPMENT
+Strain vs -Strain IBD Colon Chips (Epithelium)

Adj p-val: <0.00010
NES: 2.32

KEGG FOCAL ADHESION
+Strain vs -Strain IBD Colon Chips (Epithelium)

Adj p-val: <0.00010
NES: 2.06

KEGG CYTOKINE CYTOKINE RECEPTOR INTERACTION
+Strain vs -Strain IBD Colon Chips (Epithelium)

Adj p-val: <0.00010
NES: 2.24

KEGG ECM RECEPTOR INTERACTION
+Strain vs -Strain IBD Colon Chips (Epithelium)

Adj p-val: <0.00010
NES: 2.25

🟥 Genes more highly expressed in epithelial IBD strain homotypic

🟦 Genes more highly expressed in epithelial IBD no strain homotypic

B

KEGG CYTOKINE CYTOKINE RECEPTOR INTERACTION
+Strain vs -Strain IBD Colon Chips (Fibroblast)

Adj p-val: 0.00039
NES: 1.79

KEGG NOD LIKE RECEPTOR SIGNALING PATHWAY
+Strain vs -Strain IBD Colon Chips (Fibroblast)

Adj p-val: 0.00090
NES: 2.08

REACTOME SIGNALING BY PDGF
+Strain vs -Strain IBD Colon Chips (Fibroblast)

Adj p-val: 0.00428
NES: 2.02

REACTOME DEFECTIVE CFTR CAUSES CYSTIC FIBROSIS
+Strain vs -Strain IBD Colon Chips (Fibroblast)

Adj p-val: 0.03189
NES: 1.82

🟥 Genes more highly expressed in fibroblast IBD strain homotypic

🟦 Genes more highly expressed in fibroblast IBD no strain homotypic

Extended Data Fig. 9

Extended Data Fig. 10

Extended Data Fig. 11

Extended Data Fig. 12

Supporting Data Fig. 1